» Download Public Reports
56 reports
- Company report
- August 2012
- 3 pages
... S fiscal 2013 research priorities, subject to the company raising additional funds, are to: Complete proof of concept studies in animal models of ovarian cancer with anti prp antibodies Complete ...
April 2012
... Bank of canada (bdc) for his instrumental support in the planning and development of this conference. Thank you to our generous sponsors. Welcome as leaders from the f_inance, biopharmaceutical ...
March 2012
... And allow for earlier application of emerging therapies. Amorfix technologies are also being used to develop antibody and vaccine therapies that target dses on disease-relevant proteins as an innovative ...
March 2012
... Inflammation as well as certain nephropathies. Prometic S business is organi Ed into two distinct operating segments protein technologies and therapeutics, supported by a head office in laval, canada. Business ...
December 2012
... Clinical researc tria esign assistance Waiver of prescription drug user fees. Type 1 plasminogen deficiency Plasminogen: plasminogen is a naturally occurring protein synthesized by the liver ...
March 2012
... Offer tremendous advantages as cost-effective and safe platforms for the large-scale production of vaccines and other therapeutic proteins. Plant-derived vaccines represent a means by which to enhance ...
August 2012
... Should not divert resources from effective cervical cancer screening programs square4 hpv vaccination should be introduced as part of a coordinated strategy to prevent cervical cancer and other hpv ...
August 2012
... Information, future events or otherwise. Nothing herein should be construed as an offering of securities of the company in any jurisdictions. 3 Company overview focus vaccines / biosimilars ...